These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 38862521)

  • 1. Novel meriolin derivatives potently inhibit cell cycle progression and transcription in leukemia and lymphoma cells via inhibition of cyclin-dependent kinases (CDKs).
    Schmitt L; Hoppe J; Cea-Medina P; Bruch PM; Krings KS; Lechtenberg I; Drießen D; Peter C; Bhatia S; Dietrich S; Stork B; Fritz G; Gohlke H; Müller TJJ; Wesselborg S
    Cell Death Discov; 2024 Jun; 10(1):279. PubMed ID: 38862521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases.
    Bettayeb K; Tirado OM; Marionneau-Lambot S; Ferandin Y; Lozach O; Morris JC; Mateo-Lozano S; Drueckes P; Schächtele C; Kubbutat MH; Liger F; Marquet B; Joseph B; Echalier A; Endicott JA; Notario V; Meijer L
    Cancer Res; 2007 Sep; 67(17):8325-34. PubMed ID: 17804748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis.
    Jarry M; Lecointre C; Malleval C; Desrues L; Schouft MT; Lejoncour V; Liger F; Lyvinec G; Joseph B; Loaëc N; Meijer L; Honnorat J; Gandolfo P; Castel H
    Neuro Oncol; 2014 Nov; 16(11):1484-98. PubMed ID: 24891448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex.
    Echalier A; Bettayeb K; Ferandin Y; Lozach O; Clément M; Valette A; Liger F; Marquet B; Morris JC; Endicott JA; Joseph B; Meijer L
    J Med Chem; 2008 Feb; 51(4):737-51. PubMed ID: 18232649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel meriolin derivatives activate the mitochondrial apoptosis pathway in the presence of antiapoptotic Bcl-2.
    Schmitt L; Lechtenberg I; Drießen D; Flores-Romero H; Skowron MA; Sekeres M; Hoppe J; Krings KS; Llewellyn TR; Peter C; Stork B; Qin N; Bhatia S; Nettersheim D; Fritz G; García-Sáez AJ; Müller TJJ; Wesselborg S
    Cell Death Discov; 2024 Mar; 10(1):125. PubMed ID: 38461295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent kinase pathways as targets for cancer treatment.
    Shapiro GI
    J Clin Oncol; 2006 Apr; 24(11):1770-83. PubMed ID: 16603719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism.
    Corsino P; Horenstein N; Ostrov D; Rowe T; Law M; Barrett A; Aslanidi G; Cress WD; Law B
    J Biol Chem; 2009 Oct; 284(43):29945-55. PubMed ID: 19710018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
    Joshi KS; Rathos MJ; Joshi RD; Sivakumar M; Mascarenhas M; Kamble S; Lal B; Sharma S
    Mol Cancer Ther; 2007 Mar; 6(3):918-25. PubMed ID: 17363486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
    Frame S; Saladino C; MacKay C; Atrash B; Sheldrake P; McDonald E; Clarke PA; Workman P; Blake D; Zheleva D
    PLoS One; 2020; 15(7):e0234103. PubMed ID: 32645016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
    Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
    Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
    Kang J; Sergio CM; Sutherland RL; Musgrove EA
    BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
    Ali S; Heathcote DA; Kroll SH; Jogalekar AS; Scheiper B; Patel H; Brackow J; Siwicka A; Fuchter MJ; Periyasamy M; Tolhurst RS; Kanneganti SK; Snyder JP; Liotta DC; Aboagye EO; Barrett AG; Coombes RC
    Cancer Res; 2009 Aug; 69(15):6208-15. PubMed ID: 19638587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.
    Foster JS; Henley DC; Bukovsky A; Seth P; Wimalasena J
    Mol Cell Biol; 2001 Feb; 21(3):794-810. PubMed ID: 11154267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anticancer activity of the substituted pyridone-annelated isoindigo (5'-Cl) involves G0/G1 cell cycle arrest and inactivation of CDKs in the promyelocytic leukemia cell line HL-60.
    Saleh AM; Aljada A; El-Abadelah MM; Taha MO; Sabri SS; Zahra JA; Aziz MA
    Cell Physiol Biochem; 2015; 35(5):1943-57. PubMed ID: 25870953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
    Whittaker SR; Walton MI; Garrett MD; Workman P
    Cancer Res; 2004 Jan; 64(1):262-72. PubMed ID: 14729633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
    Mou J; Chen D; Deng Y
    Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
    Hirai H; Kawanishi N; Iwasawa Y
    Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.
    Heathcote DA; Patel H; Kroll SH; Hazel P; Periyasamy M; Alikian M; Kanneganti SK; Jogalekar AS; Scheiper B; Barbazanges M; Blum A; Brackow J; Siwicka A; Pace RD; Fuchter MJ; Snyder JP; Liotta DC; Freemont PS; Aboagye EO; Coombes RC; Barrett AG; Ali S
    J Med Chem; 2010 Dec; 53(24):8508-22. PubMed ID: 21080703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.